CA2777406A1

CA2777406A1 - Thiazolidinedione energy restriction-mimetic agents

Thiazolidinedione energy restriction-mimetic agents Download PDF

Info

Publication number: CA2777406A1
Authority: CA; Canada
Prior art keywords: benzylidene; dione; thiazolidine; methyl; compound
Prior art date: 2009-10-09
Legal status : Abandoned

Application number

CA2777406A

Other languages

English (en)

French (fr)

Inventor

Ching-Shih Chen

Jih-Hwa Guh

Current Assignee

Ohio State University Research Foundation

Original Assignee

Ohio State University Research Foundation

Priority date

2009-10-09

Filing date

2010-10-11

Publication date

2011-04-14

2010-10-11 Application filed by Ohio State University Research Foundation filed Critical Ohio State University Research Foundation

2011-04-14 Publication of CA2777406A1 publication Critical patent/CA2777406A1/en

Status Abandoned legal-status Critical Current

Links

229940123464 Thiazolidinedione Drugs 0.000 title description 61
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 title description 12
150000001467 thiazolidinediones Chemical class 0.000 claims abstract description 150
206010028980 Neoplasm Diseases 0.000 claims abstract description 113
201000011510 cancer Diseases 0.000 claims abstract description 88
230000014509 gene expression Effects 0.000 claims abstract description 77
238000000034 method Methods 0.000 claims abstract description 74
230000002401 inhibitory effect Effects 0.000 claims abstract description 37
230000034659 glycolysis Effects 0.000 claims abstract description 28
102000004889 Interleukin-6 Human genes 0.000 claims abstract description 27
108090001005 Interleukin-6 Proteins 0.000 claims abstract description 27
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 19
230000003213 activating effect Effects 0.000 claims abstract description 13
102000014156 AMP-Activated Protein Kinases Human genes 0.000 claims description 128
108010011376 AMP-Activated Protein Kinases Proteins 0.000 claims description 128
150000001875 compounds Chemical class 0.000 claims description 113
MADFJWDIMPOGOZ-GDNBJRDFSA-N (5z)-5-[[4-hydroxy-3-(trifluoromethyl)phenyl]methylidene]-3-[(1-methylcyclohexyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound O=C1S\C(=C/C=2C=C(C(O)=CC=2)C(F)(F)F)C(=O)N1CC1(C)CCCCC1 MADFJWDIMPOGOZ-GDNBJRDFSA-N 0.000 claims description 92
-1 amino, methyl Chemical group 0.000 claims description 43
125000000217 alkyl group Chemical group 0.000 claims description 38
229910052739 hydrogen Inorganic materials 0.000 claims description 25
239000001257 hydrogen Substances 0.000 claims description 25
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 23
125000005843 halogen group Chemical group 0.000 claims description 18
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 17
125000000753 cycloalkyl group Chemical group 0.000 claims description 15
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 14
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
125000003118 aryl group Chemical group 0.000 claims description 12
125000001188 haloalkyl group Chemical group 0.000 claims description 9
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 9
125000003342 alkenyl group Chemical group 0.000 claims description 7
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 7
125000001072 heteroaryl group Chemical group 0.000 claims description 6
NNHISQOAXRMKEQ-UHFFFAOYSA-N 4-[[2-[[2-bromo-4-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]phenoxy]methyl]-2,5,7,8-tetramethyl-3,4-dihydrochromen-6-yl]oxy]butanenitrile Chemical compound C1CC=2C(C)=C(OCCCC#N)C(C)=C(C)C=2OC1(C)COC(C(=C1)Br)=CC=C1C=C1SC(=O)NC1=O NNHISQOAXRMKEQ-UHFFFAOYSA-N 0.000 claims description 5
DKGMGNBUZOAOCL-UHFFFAOYSA-N 5-[[3-bromo-4-[(6-ethoxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1CC2=C(C)C(OCC)=C(C)C(C)=C2OC1(C)COC(C(=C1)Br)=CC=C1C=C1SC(=O)NC1=O DKGMGNBUZOAOCL-UHFFFAOYSA-N 0.000 claims description 5
125000003545 alkoxy group Chemical group 0.000 claims description 5
CSLBUUVXPNRUAH-UHFFFAOYSA-N 5-[[4-hydroxy-3-(trifluoromethyl)phenyl]methylidene]-3-propyl-1,3-thiazolidine-2,4-dione Chemical compound O=C1N(CCC)C(=O)SC1=CC1=CC=C(O)C(C(F)(F)F)=C1 CSLBUUVXPNRUAH-UHFFFAOYSA-N 0.000 claims description 4
125000001246 bromo group Chemical group Br* 0.000 claims description 4
TWLXALMZQJPFFI-UHFFFAOYSA-N n-[4-[[3-[(1-methylcyclohexyl)methyl]-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl]phenyl]-4-nitrobenzenesulfonamide Chemical compound O=C1SC(=CC=2C=CC(NS(=O)(=O)C=3C=CC(=CC=3)[N+]([O-])=O)=CC=2)C(=O)N1CC1(C)CCCCC1 TWLXALMZQJPFFI-UHFFFAOYSA-N 0.000 claims description 4
MADFJWDIMPOGOZ-UHFFFAOYSA-N 5-[[4-hydroxy-3-(trifluoromethyl)phenyl]methylidene]-3-[(1-methylcyclohexyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound O=C1SC(=CC=2C=C(C(O)=CC=2)C(F)(F)F)C(=O)N1CC1(C)CCCCC1 MADFJWDIMPOGOZ-UHFFFAOYSA-N 0.000 claims description 3
125000000592 heterocycloalkyl group Chemical group 0.000 claims description 2
FANMQRSNMHKZCR-UHFFFAOYSA-N n-[4-[[3-[(1-methylcyclohexyl)methyl]-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl]phenyl]-4-nitro-3-(trifluoromethyl)benzenesulfonamide Chemical compound O=C1SC(=CC=2C=CC(NS(=O)(=O)C=3C=C(C(=CC=3)[N+]([O-])=O)C(F)(F)F)=CC=2)C(=O)N1CC1(C)CCCCC1 FANMQRSNMHKZCR-UHFFFAOYSA-N 0.000 claims 3
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 abstract description 71
208000030159 metabolic disease Diseases 0.000 abstract description 4
UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 abstract 1
102000001253 Protein Kinase Human genes 0.000 abstract 1
UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 abstract 1
229950006790 adenosine phosphate Drugs 0.000 abstract 1
108060006633 protein kinase Proteins 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 189
230000000694 effects Effects 0.000 description 102
230000004913 activation Effects 0.000 description 57
VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 description 51
PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 description 51
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 45
239000008103 glucose Substances 0.000 description 44
YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 40
229950009226 ciglitazone Drugs 0.000 description 40
108090000623 proteins and genes Proteins 0.000 description 40
238000011282 treatment Methods 0.000 description 37
QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 34
LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 34
230000005764 inhibitory process Effects 0.000 description 34
230000001404 mediated effect Effects 0.000 description 34
102000004169 proteins and genes Human genes 0.000 description 34
229940016667 resveratrol Drugs 0.000 description 34
235000021283 resveratrol Nutrition 0.000 description 34
239000002158 endotoxin Substances 0.000 description 31
229920006008 lipopolysaccharide Polymers 0.000 description 31
239000003814 drug Substances 0.000 description 29
230000004900 autophagic degradation Effects 0.000 description 28
229940079593 drug Drugs 0.000 description 28
210000002472 endoplasmic reticulum Anatomy 0.000 description 28
230000026731 phosphorylation Effects 0.000 description 27
238000006366 phosphorylation reaction Methods 0.000 description 27
229940126545 compound 53 Drugs 0.000 description 25
230000017306 interleukin-6 production Effects 0.000 description 25
FDBYIYFVSAHJLY-UHFFFAOYSA-N resmetirom Chemical compound N1C(=O)C(C(C)C)=CC(OC=2C(=CC(=CC=2Cl)N2C(NC(=O)C(C#N)=N2)=O)Cl)=N1 FDBYIYFVSAHJLY-UHFFFAOYSA-N 0.000 description 25
210000002540 macrophage Anatomy 0.000 description 22
230000035882 stress Effects 0.000 description 22
230000006698 induction Effects 0.000 description 20
239000002609 medium Substances 0.000 description 20
230000036515 potency Effects 0.000 description 20
230000036755 cellular response Effects 0.000 description 19
230000037149 energy metabolism Effects 0.000 description 19
235000003642 hunger Nutrition 0.000 description 19
238000003119 immunoblot Methods 0.000 description 19
230000037351 starvation Effects 0.000 description 19
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 18
108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 18
238000002474 experimental method Methods 0.000 description 18
230000011664 signaling Effects 0.000 description 18
108091003079 Bovine Serum Albumin Proteins 0.000 description 17
230000006907 apoptotic process Effects 0.000 description 17
239000012091 fetal bovine serum Substances 0.000 description 17
230000007246 mechanism Effects 0.000 description 17
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 17
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
230000001028 anti-proliverative effect Effects 0.000 description 16
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
229960001641 troglitazone Drugs 0.000 description 16
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 16
230000003827 upregulation Effects 0.000 description 16
238000001262 western blot Methods 0.000 description 16
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
230000004044 response Effects 0.000 description 15
230000001419 dependent effect Effects 0.000 description 14
230000004190 glucose uptake Effects 0.000 description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 13
102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 13
101000795659 Homo sapiens Tuberin Proteins 0.000 description 13
102100031638 Tuberin Human genes 0.000 description 13
239000012190 activator Substances 0.000 description 13
201000010099 disease Diseases 0.000 description 13
231100000673 dose–response relationship Toxicity 0.000 description 13
230000012010 growth Effects 0.000 description 13
150000003839 salts Chemical class 0.000 description 13
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
101150112743 HSPA5 gene Proteins 0.000 description 12
101100111629 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR2 gene Proteins 0.000 description 12
125000004432 carbon atom Chemical group C* 0.000 description 12
230000002414 glycolytic effect Effects 0.000 description 12
101150028578 grp78 gene Proteins 0.000 description 12
230000001965 increasing effect Effects 0.000 description 12
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 12
BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 12
230000017854 proteolysis Effects 0.000 description 12
230000004063 proteosomal degradation Effects 0.000 description 12
230000002829 reductive effect Effects 0.000 description 12
229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 11
230000015572 biosynthetic process Effects 0.000 description 11
230000030833 cell death Effects 0.000 description 11
230000007423 decrease Effects 0.000 description 11
230000006870 function Effects 0.000 description 11
238000004519 manufacturing process Methods 0.000 description 11
239000011734 sodium Substances 0.000 description 11
239000000126 substance Substances 0.000 description 11
108050006400 Cyclin Proteins 0.000 description 10
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 10
DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 10
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 10
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
230000000259 anti-tumor effect Effects 0.000 description 10
230000003833 cell viability Effects 0.000 description 10
238000003776 cleavage reaction Methods 0.000 description 10
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
239000000203 mixture Substances 0.000 description 10
230000037361 pathway Effects 0.000 description 10
230000007017 scission Effects 0.000 description 10
238000012216 screening Methods 0.000 description 10
125000001424 substituent group Chemical group 0.000 description 10
230000008685 targeting Effects 0.000 description 10
230000001052 transient effect Effects 0.000 description 10
AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 9
102100032187 Androgen receptor Human genes 0.000 description 9
206010060862 Prostate cancer Diseases 0.000 description 9
208000000236 Prostatic Neoplasms Diseases 0.000 description 9
108010080146 androgen receptors Proteins 0.000 description 9
239000000090 biomarker Substances 0.000 description 9
230000000903 blocking effect Effects 0.000 description 9
230000005014 ectopic expression Effects 0.000 description 9
108020004999 messenger RNA Proteins 0.000 description 9
230000019261 negative regulation of glycolysis Effects 0.000 description 9
239000013612 plasmid Substances 0.000 description 9
210000000064 prostate epithelial cell Anatomy 0.000 description 9
101150041968 CDC13 gene Proteins 0.000 description 8
102000016736 Cyclin Human genes 0.000 description 8
241000699670 Mus sp. Species 0.000 description 8
239000012980 RPMI-1640 medium Substances 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
238000003556 assay Methods 0.000 description 8
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 8
230000001413 cellular effect Effects 0.000 description 8
230000002503 metabolic effect Effects 0.000 description 8
239000000758 substrate Substances 0.000 description 8
230000001629 suppression Effects 0.000 description 8
238000012360 testing method Methods 0.000 description 8
208000001072 type 2 diabetes mellitus Diseases 0.000 description 8
238000005160 1H NMR spectroscopy Methods 0.000 description 7
ZPBYVFQJHWLTFB-UHFFFAOYSA-N 3-methyl-7H-purin-6-imine Chemical compound CN1C=NC(=N)C2=C1NC=N2 ZPBYVFQJHWLTFB-UHFFFAOYSA-N 0.000 description 7
238000002965 ELISA Methods 0.000 description 7
101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 7
108091027967 Small hairpin RNA Proteins 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
230000006536 aerobic glycolysis Effects 0.000 description 7
238000010171 animal model Methods 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
125000004122 cyclic group Chemical group 0.000 description 7
YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 7
230000009038 pharmacological inhibition Effects 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
239000004055 small Interfering RNA Substances 0.000 description 7
230000000153 supplemental effect Effects 0.000 description 7
238000003786 synthesis reaction Methods 0.000 description 7
230000035899 viability Effects 0.000 description 7
206010006187 Breast cancer Diseases 0.000 description 6
208000026310 Breast neoplasm Diseases 0.000 description 6
108010058546 Cyclin D1 Proteins 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 6
208000001145 Metabolic Syndrome Diseases 0.000 description 6
102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 6
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
101150099493 STAT3 gene Proteins 0.000 description 6
108020004459 Small interfering RNA Proteins 0.000 description 6
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 6
125000001931 aliphatic group Chemical group 0.000 description 6
230000000875 corresponding effect Effects 0.000 description 6
238000005421 electrostatic potential Methods 0.000 description 6
230000003211 malignant effect Effects 0.000 description 6
230000003389 potentiating effect Effects 0.000 description 6
230000019491 signal transduction Effects 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
239000013598 vector Substances 0.000 description 6
238000005406 washing Methods 0.000 description 6
ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 5
208000005623 Carcinogenesis Diseases 0.000 description 5
102000001301 EGF receptor Human genes 0.000 description 5
108060006698 EGF receptor Proteins 0.000 description 5
102000004877 Insulin Human genes 0.000 description 5
108090001061 Insulin Proteins 0.000 description 5
206010022489 Insulin Resistance Diseases 0.000 description 5
238000000134 MTT assay Methods 0.000 description 5
231100000002 MTT assay Toxicity 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
108091000080 Phosphotransferase Proteins 0.000 description 5
238000010240 RT-PCR analysis Methods 0.000 description 5
230000006682 Warburg effect Effects 0.000 description 5
239000002253 acid Substances 0.000 description 5
230000008901 benefit Effects 0.000 description 5
230000036952 cancer formation Effects 0.000 description 5
231100000504 carcinogenesis Toxicity 0.000 description 5
101150116749 chuk gene Proteins 0.000 description 5
230000003247 decreasing effect Effects 0.000 description 5
235000019441 ethanol Nutrition 0.000 description 5
230000007946 glucose deprivation Effects 0.000 description 5
230000004153 glucose metabolism Effects 0.000 description 5
230000009036 growth inhibition Effects 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
229940125396 insulin Drugs 0.000 description 5
230000003834 intracellular effect Effects 0.000 description 5
210000003470 mitochondria Anatomy 0.000 description 5
229960003966 nicotinamide Drugs 0.000 description 5
235000005152 nicotinamide Nutrition 0.000 description 5
239000011570 nicotinamide Substances 0.000 description 5
102000020233 phosphotransferase Human genes 0.000 description 5
229910000027 potassium carbonate Inorganic materials 0.000 description 5
230000009467 reduction Effects 0.000 description 5
238000010992 reflux Methods 0.000 description 5
230000016914 response to endoplasmic reticulum stress Effects 0.000 description 5
ISFPDBUKMJDAJH-UHFFFAOYSA-N splitomicin Chemical compound C1=CC2=CC=CC=C2C2=C1OC(=O)CC2 ISFPDBUKMJDAJH-UHFFFAOYSA-N 0.000 description 5
230000005919 time-dependent effect Effects 0.000 description 5
FSASIHFSFGAIJM-UHFFFAOYSA-N 3MeA Natural products CN1C=NC(N)=C2N=CN=C12 FSASIHFSFGAIJM-UHFFFAOYSA-N 0.000 description 4
102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 4
108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 4
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
102000015696 Interleukins Human genes 0.000 description 4
108010063738 Interleukins Proteins 0.000 description 4
238000005481 NMR spectroscopy Methods 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
238000009825 accumulation Methods 0.000 description 4
230000009471 action Effects 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
210000001789 adipocyte Anatomy 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
239000002585 base Substances 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
230000037396 body weight Effects 0.000 description 4
230000010261 cell growth Effects 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
208000029742 colonic neoplasm Diseases 0.000 description 4
230000006196 deacetylation Effects 0.000 description 4
238000003381 deacetylation reaction Methods 0.000 description 4
235000005911 diet Nutrition 0.000 description 4
230000000378 dietary effect Effects 0.000 description 4
235000014113 dietary fatty acids Nutrition 0.000 description 4
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 4
239000000194 fatty acid Substances 0.000 description 4
229930195729 fatty acid Natural products 0.000 description 4
150000004665 fatty acids Chemical class 0.000 description 4
238000000799 fluorescence microscopy Methods 0.000 description 4
238000009472 formulation Methods 0.000 description 4
125000005842 heteroatom Chemical group 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
238000011534 incubation Methods 0.000 description 4
208000032839 leukemia Diseases 0.000 description 4
239000000463 material Substances 0.000 description 4
231100000682 maximum tolerated dose Toxicity 0.000 description 4
239000012528 membrane Substances 0.000 description 4
230000003278 mimic effect Effects 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
230000002265 prevention Effects 0.000 description 4
239000000047 product Substances 0.000 description 4
102220142342 rs779117189 Human genes 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000007787 solid Substances 0.000 description 4
238000010186 staining Methods 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
239000000725 suspension Substances 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
XSHQNYOGFPQFQI-UHFFFAOYSA-N (1-methylcyclohexyl)methyl trifluoromethanesulfonate Chemical compound FC(F)(F)S(=O)(=O)OCC1(C)CCCCC1 XSHQNYOGFPQFQI-UHFFFAOYSA-N 0.000 description 3
IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 3
WQTPXJJRGXOPNH-UHFFFAOYSA-N 4-(hydroxymethyl)-n-[4-nitro-3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound C1=CC(CO)=CC=C1S(=O)(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 WQTPXJJRGXOPNH-UHFFFAOYSA-N 0.000 description 3
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
RTRQQBHATOEIAF-UHFFFAOYSA-N AICA riboside Natural products NC1=C(C(=O)N)N=CN1C1C(O)C(O)C(CO)O1 RTRQQBHATOEIAF-UHFFFAOYSA-N 0.000 description 3
102000005483 Cell Cycle Proteins Human genes 0.000 description 3
108010031896 Cell Cycle Proteins Proteins 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 3
108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
102000001267 GSK3 Human genes 0.000 description 3
108060006662 GSK3 Proteins 0.000 description 3
102000010781 Interleukin-6 Receptors Human genes 0.000 description 3
108010038501 Interleukin-6 Receptors Proteins 0.000 description 3
108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 3
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
229930182816 L-glutamine Natural products 0.000 description 3
239000005089 Luciferase Substances 0.000 description 3
102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 3
BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 3
108010017324 STAT3 Transcription Factor Proteins 0.000 description 3
102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 3
102100036221 Tax1-binding protein 3 Human genes 0.000 description 3
101710193790 Tax1-binding protein 3 Proteins 0.000 description 3
RTRQQBHATOEIAF-UUOKFMHZSA-N acadesine Chemical compound NC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RTRQQBHATOEIAF-UUOKFMHZSA-N 0.000 description 3
230000006978 adaptation Effects 0.000 description 3
125000002947 alkylene group Chemical group 0.000 description 3
125000000732 arylene group Chemical group 0.000 description 3
230000005033 autophagosome formation Effects 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
239000012267 brine Substances 0.000 description 3
239000000872 buffer Substances 0.000 description 3
235000020934 caloric restriction Nutrition 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
238000000423 cell based assay Methods 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
230000019522 cellular metabolic process Effects 0.000 description 3
230000005754 cellular signaling Effects 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
238000001514 detection method Methods 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
230000007783 downstream signaling Effects 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
230000030279 gene silencing Effects 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000011065 in-situ storage Methods 0.000 description 3
230000003993 interaction Effects 0.000 description 3
230000037041 intracellular level Effects 0.000 description 3
238000011835 investigation Methods 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
238000007431 microscopic evaluation Methods 0.000 description 3
NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 3
238000011275 oncology therapy Methods 0.000 description 3
150000007524 organic acids Chemical class 0.000 description 3
108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 3
210000002307 prostate Anatomy 0.000 description 3
230000029983 protein stabilization Effects 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
229940076788 pyruvate Drugs 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
230000028327 secretion Effects 0.000 description 3
230000007781 signaling event Effects 0.000 description 3
238000010898 silica gel chromatography Methods 0.000 description 3
150000003384 small molecules Chemical class 0.000 description 3
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
239000000243 solution Substances 0.000 description 3
230000006641 stabilisation Effects 0.000 description 3
238000011105 stabilization Methods 0.000 description 3
229910052717 sulfur Inorganic materials 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
230000036962 time dependent Effects 0.000 description 3
238000003146 transient transfection Methods 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
GZCGUPFRVQAUEE-CPMQAFPASA-N (2r,3s,4s,5r)-2,3,4,5,6-pentahydroxy-5-tritiohexanal Chemical compound OC[C@](O)([3H])[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-CPMQAFPASA-N 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 description 2
SGIZECXZFLAGBW-UHFFFAOYSA-N 5-benzylidene-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1=CC1=CC=CC=C1 SGIZECXZFLAGBW-UHFFFAOYSA-N 0.000 description 2
101001059929 Caenorhabditis elegans Forkhead box protein O Proteins 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 2
108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
108010044467 Isoenzymes Proteins 0.000 description 2
208000008839 Kidney Neoplasms Diseases 0.000 description 2
108060001084 Luciferase Proteins 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
206010033128 Ovarian cancer Diseases 0.000 description 2
206010061535 Ovarian neoplasm Diseases 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 2
238000002123 RNA extraction Methods 0.000 description 2
101710137877 Regulatory protein SIR1 Proteins 0.000 description 2
206010038389 Renal cancer Diseases 0.000 description 2
108091027981 Response element Proteins 0.000 description 2
102000009738 Ribosomal Protein S6 Kinases Human genes 0.000 description 2
108010034782 Ribosomal Protein S6 Kinases Proteins 0.000 description 2
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
239000012722 SDS sample buffer Substances 0.000 description 2
101710127774 Stress response protein Proteins 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
102000004061 Transcription Factor CHOP Human genes 0.000 description 2
108010057666 Transcription Factor CHOP Proteins 0.000 description 2
108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 2
108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 2
102100036976 X-ray repair cross-complementing protein 6 Human genes 0.000 description 2
101710124907 X-ray repair cross-complementing protein 6 Proteins 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
101150063416 add gene Proteins 0.000 description 2
208000009956 adenocarcinoma Diseases 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
230000002411 adverse Effects 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
125000004450 alkenylene group Chemical group 0.000 description 2
125000000304 alkynyl group Chemical group 0.000 description 2
230000008856 allosteric binding Effects 0.000 description 2
230000001093 anti-cancer Effects 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
238000003149 assay kit Methods 0.000 description 2
238000011717 athymic nude mouse Methods 0.000 description 2
230000002886 autophagic effect Effects 0.000 description 2
230000027455 binding Effects 0.000 description 2
230000009702 cancer cell proliferation Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000022131 cell cycle Effects 0.000 description 2
230000025084 cell cycle arrest Effects 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
201000007455 central nervous system cancer Diseases 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
238000011278 co-treatment Methods 0.000 description 2
201000010897 colon adenocarcinoma Diseases 0.000 description 2
230000030609 dephosphorylation Effects 0.000 description 2
238000006209 dephosphorylation reaction Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
238000010586 diagram Methods 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
230000003828 downregulation Effects 0.000 description 2
230000000857 drug effect Effects 0.000 description 2
239000012636 effector Substances 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
229960005542 ethidium bromide Drugs 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
239000000284 extract Substances 0.000 description 2
238000003818 flash chromatography Methods 0.000 description 2
239000000446 fuel Substances 0.000 description 2
231100000722 genetic damage Toxicity 0.000 description 2
230000014101 glucose homeostasis Effects 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
125000005549 heteroarylene group Chemical group 0.000 description 2
150000002430 hydrocarbons Chemical group 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
230000002601 intratumoral effect Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
201000010982 kidney cancer Diseases 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000003446 ligand Substances 0.000 description 2
239000006166 lysate Substances 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000005259 measurement Methods 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
235000013336 milk Nutrition 0.000 description 2
239000008267 milk Substances 0.000 description 2
210000004080 milk Anatomy 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
230000002438 mitochondrial effect Effects 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
125000000962 organic group Chemical group 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
230000001151 other effect Effects 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
230000036542 oxidative stress Effects 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
239000012660 pharmacological inhibitor Substances 0.000 description 2
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
238000002600 positron emission tomography Methods 0.000 description 2
235000015320 potassium carbonate Nutrition 0.000 description 2
229920001592 potato starch Polymers 0.000 description 2
230000008569 process Effects 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
238000003757 reverse transcription PCR Methods 0.000 description 2
238000012552 review Methods 0.000 description 2
239000000523 sample Substances 0.000 description 2
229930195734 saturated hydrocarbon Natural products 0.000 description 2
102000034285 signal transducing proteins Human genes 0.000 description 2
108091006024 signal transducing proteins Proteins 0.000 description 2
235000017550 sodium carbonate Nutrition 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
230000006354 stress signaling Effects 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
239000003826 tablet Substances 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
230000037426 transcriptional repression Effects 0.000 description 2
238000001890 transfection Methods 0.000 description 2
230000004102 tricarboxylic acid cycle Effects 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
210000003934 vacuole Anatomy 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical group C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
REHQLKUNRPCYEW-UHFFFAOYSA-N 1-methylcyclohexane-1-carboxylic acid Chemical compound OC(=O)C1(C)CCCCC1 REHQLKUNRPCYEW-UHFFFAOYSA-N 0.000 description 1
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical group C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
HBAHZZVIEFRTEY-UHFFFAOYSA-N 2-heptylcyclohex-2-en-1-one Chemical compound CCCCCCCC1=CCCCC1=O HBAHZZVIEFRTEY-UHFFFAOYSA-N 0.000 description 1
BUOYTFVLNZIELF-UHFFFAOYSA-N 2-phenyl-1h-indole-4,6-dicarboximidamide Chemical compound N1C2=CC(C(=N)N)=CC(C(N)=N)=C2C=C1C1=CC=CC=C1 BUOYTFVLNZIELF-UHFFFAOYSA-N 0.000 description 1
108050001326 26S Proteasome regulatory subunit 6A Proteins 0.000 description 1
102100029510 26S proteasome regulatory subunit 6A Human genes 0.000 description 1
SOJABWISUANRQF-UHFFFAOYSA-N 3-[(1-methylcyclohexyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1CC1(C)CCCCC1 SOJABWISUANRQF-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
LJQUNSRHHHYXEW-UHFFFAOYSA-N 4-nitro-3-(trifluoromethyl)benzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(S(Cl)(=O)=O)C=C1C(F)(F)F LJQUNSRHHHYXEW-UHFFFAOYSA-N 0.000 description 1
MPLLLQUZNJSVTK-UHFFFAOYSA-N 5-[3-[4-[2-(4-fluorophenyl)ethoxy]phenyl]propyl]furan-2-carboxylic acid Chemical compound O1C(C(=O)O)=CC=C1CCCC(C=C1)=CC=C1OCCC1=CC=C(F)C=C1 MPLLLQUZNJSVTK-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
230000002407 ATP formation Effects 0.000 description 1
208000004611 Abdominal Obesity Diseases 0.000 description 1
102000014777 Adipokines Human genes 0.000 description 1
108010078606 Adipokines Proteins 0.000 description 1
102000011690 Adiponectin Human genes 0.000 description 1
108010076365 Adiponectin Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
101100096476 Bacillus subtilis (strain 168) splB gene Proteins 0.000 description 1
101100478849 Bifidobacterium adolescentis (strain ATCC 15703 / DSM 20083 / NCTC 11814 / E194a) sucP gene Proteins 0.000 description 1
229940122361 Bisphosphonate Drugs 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
206010006895 Cachexia Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000283707 Capra Species 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
206010065941 Central obesity Diseases 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
229940126639 Compound 33 Drugs 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
238000004057 DFT-B3LYP calculation Methods 0.000 description 1
230000005971 DNA damage repair Effects 0.000 description 1
230000033616 DNA repair Effects 0.000 description 1
102100026816 DNA-dependent metalloprotease SPRTN Human genes 0.000 description 1
101710175461 DNA-dependent metalloprotease SPRTN Proteins 0.000 description 1
238000003775 Density Functional Theory Methods 0.000 description 1
101100421425 Drosophila melanogaster Sply gene Proteins 0.000 description 1
206010052804 Drug tolerance Diseases 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
206010014486 Elevated triglycerides Diseases 0.000 description 1
102100030013 Endoribonuclease Human genes 0.000 description 1
101710199605 Endoribonuclease Proteins 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
102000018700 F-Box Proteins Human genes 0.000 description 1
108010066805 F-Box Proteins Proteins 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
HILUWRPVFKJTAD-ZGHMGGRHSA-N GA21 Chemical compound O=C(O)[C@H]1[C@@H]2[C@]3(C(=O)O)C(=O)O[C@@]2([C@H]2[C@]41CC(=C)[C@@](O)(C4)CC2)CCC3 HILUWRPVFKJTAD-ZGHMGGRHSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
208000002705 Glucose Intolerance Diseases 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229920002527 Glycogen Polymers 0.000 description 1
208000012766 Growth delay Diseases 0.000 description 1
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
102000005548 Hexokinase Human genes 0.000 description 1
108700040460 Hexokinases Proteins 0.000 description 1
102000003964 Histone deacetylase Human genes 0.000 description 1
108090000353 Histone deacetylase Proteins 0.000 description 1
101000968229 Homo sapiens DDIT3 upstream open reading frame protein Proteins 0.000 description 1
101000731000 Homo sapiens Membrane-associated progesterone receptor component 1 Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010056997 Impaired fasting glucose Diseases 0.000 description 1
101710176220 Kallikrein-2 Proteins 0.000 description 1
JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
102000043136 MAP kinase family Human genes 0.000 description 1
108091054455 MAP kinase family Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
102100032399 Membrane-associated progesterone receptor component 1 Human genes 0.000 description 1
229920001367 Merrifield resin Polymers 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
108010020004 Microtubule-Associated Proteins Proteins 0.000 description 1
238000006751 Mitsunobu reaction Methods 0.000 description 1
238000000342 Monte Carlo simulation Methods 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
102000048850 Neoplasm Genes Human genes 0.000 description 1
108700019961 Neoplasm Genes Proteins 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
238000010222 PCR analysis Methods 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
229940122907 Phosphatase inhibitor Drugs 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 1
102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
241000288906 Primates Species 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
238000011530 RNeasy Mini Kit Methods 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
241000700159 Rattus Species 0.000 description 1
108050002653 Retinoblastoma protein Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
101150099060 SGPL1 gene Proteins 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
108700012920 TNF Proteins 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
102000057032 Tissue Kallikreins Human genes 0.000 description 1
102000008233 Toll-Like Receptor 4 Human genes 0.000 description 1
108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
108700019205 Tuberous Sclerosis Complex 2 Proteins 0.000 description 1
102000044633 Tuberous Sclerosis Complex 2 Human genes 0.000 description 1
208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000011481 absorbance measurement Methods 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
230000002730 additional effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
239000000478 adipokine Substances 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
239000000556 agonist Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
125000002877 alkyl aryl group Chemical group 0.000 description 1
125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
125000005466 alkylenyl group Chemical group 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
238000011394 anticancer treatment Methods 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000001908 autoinhibitory effect Effects 0.000 description 1
230000009789 autophagic cell death Effects 0.000 description 1
239000012822 autophagy inhibitor Substances 0.000 description 1
150000003935 benzaldehydes Chemical class 0.000 description 1
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
239000004305 biphenyl Chemical group 0.000 description 1
235000010290 biphenyl Nutrition 0.000 description 1
150000004663 bisphosphonates Chemical class 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
235000019577 caloric intake Nutrition 0.000 description 1
235000020827 calorie restriction Nutrition 0.000 description 1
230000005880 cancer cell killing Effects 0.000 description 1
230000005907 cancer growth Effects 0.000 description 1
125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
125000004181 carboxyalkyl group Chemical group 0.000 description 1
239000003183 carcinogenic agent Substances 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
230000001364 causal effect Effects 0.000 description 1
230000018486 cell cycle phase Effects 0.000 description 1
230000006369 cell cycle progression Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
238000003570 cell viability assay Methods 0.000 description 1
230000006567 cellular energy metabolism Effects 0.000 description 1
230000010001 cellular homeostasis Effects 0.000 description 1
230000004637 cellular stress Effects 0.000 description 1
230000004700 cellular uptake Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
230000002925 chemical effect Effects 0.000 description 1
239000013626 chemical specie Substances 0.000 description 1
230000002113 chemopreventative effect Effects 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
229960002023 chloroprocaine Drugs 0.000 description 1
229960003677 chloroquine Drugs 0.000 description 1
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000004966 cyanoalkyl group Chemical group 0.000 description 1
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
210000000172 cytosol Anatomy 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000000850 deacetylating effect Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
229940043237 diethanolamine Drugs 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
235000019800 disodium phosphate Nutrition 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000007877 drug screening Methods 0.000 description 1
230000000547 effect on apoptosis Effects 0.000 description 1
238000001378 electrochemiluminescence detection Methods 0.000 description 1
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
230000009881 electrostatic interaction Effects 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
230000003028 elevating effect Effects 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
238000005265 energy consumption Methods 0.000 description 1
230000019439 energy homeostasis Effects 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000008995 epigenetic change Effects 0.000 description 1
230000008472 epithelial growth Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
125000001033 ether group Chemical group 0.000 description 1
229940012017 ethylenediamine Drugs 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
235000013861 fat-free Nutrition 0.000 description 1
230000004129 fatty acid metabolism Effects 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
229930003935 flavonoid Natural products 0.000 description 1
150000002215 flavonoids Chemical class 0.000 description 1
235000017173 flavonoids Nutrition 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
238000003304 gavage Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
108010017007 glucose-regulated proteins Proteins 0.000 description 1
230000036252 glycation Effects 0.000 description 1
230000002641 glycemic effect Effects 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
229940096919 glycogen Drugs 0.000 description 1
230000006545 glycolytic metabolism Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000009422 growth inhibiting effect Effects 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
102000055172 human DDIT3 Human genes 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
125000002768 hydroxyalkyl group Chemical group 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
230000006882 induction of apoptosis Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
229960000367 inositol Drugs 0.000 description 1
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
229940116871 l-lactate Drugs 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000008101 lactose Substances 0.000 description 1
206010024627 liposarcoma Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
238000003468 luciferase reporter gene assay Methods 0.000 description 1
LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
235000009498 luteolin Nutrition 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
210000005075 mammary gland Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000003550 marker Substances 0.000 description 1
108010082117 matrigel Proteins 0.000 description 1
201000000083 maturity-onset diabetes of the young type 1 Diseases 0.000 description 1
229960003194 meglumine Drugs 0.000 description 1
230000004066 metabolic change Effects 0.000 description 1
230000037353 metabolic pathway Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000006609 metabolic stress Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
OSRSEQQKMVCKTI-UHFFFAOYSA-N methyl 4-[[4-nitro-3-(trifluoromethyl)phenyl]sulfamoyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1S(=O)(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 OSRSEQQKMVCKTI-UHFFFAOYSA-N 0.000 description 1
LZXXNPOYQCLXRS-UHFFFAOYSA-N methyl 4-aminobenzoate Chemical compound COC(=O)C1=CC=C(N)C=C1 LZXXNPOYQCLXRS-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
238000001000 micrograph Methods 0.000 description 1
210000004088 microvessel Anatomy 0.000 description 1
230000008437 mitochondrial biogenesis Effects 0.000 description 1
230000001832 mitochondrialike Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000003032 molecular docking Methods 0.000 description 1
238000000302 molecular modelling Methods 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
239000012120 mounting media Substances 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
229940124303 multikinase inhibitor Drugs 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
125000004971 nitroalkyl group Chemical group 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 1
125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
238000010534 nucleophilic substitution reaction Methods 0.000 description 1
235000021231 nutrient uptake Nutrition 0.000 description 1
231100000590 oncogenic Toxicity 0.000 description 1
230000002246 oncogenic effect Effects 0.000 description 1
238000003305 oral gavage Methods 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
125000001715 oxadiazolyl group Chemical group 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
230000006611 pharmacological activation Effects 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
XLCISDOVNFLSGO-VONOSFMSSA-N phorbol-12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(O)C1(C)C XLCISDOVNFLSGO-VONOSFMSSA-N 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
229960005095 pioglitazone Drugs 0.000 description 1
238000007747 plating Methods 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
125000003367 polycyclic group Chemical group 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
235000013824 polyphenols Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
231100000683 possible toxicity Toxicity 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
210000000229 preadipocyte Anatomy 0.000 description 1
239000002243 precursor Substances 0.000 description 1
201000009104 prediabetes syndrome Diseases 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
238000000751 protein extraction Methods 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
239000003642 reactive oxygen metabolite Substances 0.000 description 1
230000025512 regulation of interleukin-6 production Effects 0.000 description 1
230000009712 regulation of translation Effects 0.000 description 1
238000009877 rendering Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
230000003938 response to stress Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
229960004586 rosiglitazone Drugs 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000002000 scavenging effect Effects 0.000 description 1
238000012106 screening analysis Methods 0.000 description 1
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000028201 sequestering of triglyceride Effects 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
238000004088 simulation Methods 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
239000012453 solvate Substances 0.000 description 1
241000894007 species Species 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000003153 stable transfection Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
229960001796 sunitinib Drugs 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
125000001113 thiadiazolyl group Chemical group 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000014616 translation Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
125000004306 triazinyl group Chemical group 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
239000003656 tris buffered saline Substances 0.000 description 1
208000009999 tuberous sclerosis Diseases 0.000 description 1
230000005747 tumor angiogenesis Effects 0.000 description 1
239000000717 tumor promoter Substances 0.000 description 1
230000005760 tumorsuppression Effects 0.000 description 1
238000010200 validation analysis Methods 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
108010047303 von Willebrand Factor Proteins 0.000 description 1
102100036537 von Willebrand factor Human genes 0.000 description 1
208000016261 weight loss Diseases 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1
XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
229960004276 zoledronic acid Drugs 0.000 description 1